Lotus Pharmaceutical Co., Ltd. · TWSE:1795
Lotus Pharmaceutical — H1 2026 Earnings Presentation
19 slides from Lotus Pharmaceutical's earnings presentation, Aug 14, 2026
Slide 1: Lotus Pharmaceutical 1H26 Financial Results
Lotus Pharmaceutical 1H26 Financial Results 14 August 2026
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Except for historical information contained herein, the matters set forth in this presentation are forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These forward looking statements are not based on hi
Slide 3: Agenda
3 Agenda 1. 1H26 BUSINESS HIGHLIGHTS 2. 1H26 FINANCIAL RESULTS 3. LOTUS BUSINESS UPDATE
Slide 4: Business Highlights
01 BUSINESS HIGHLIGHTS
Slide 5: Record Revenue in 1H 2026, Improved Second-Quarter Profitability
Record Revenue in 1H 2026, Improved Second-Quarter Profitability 5 YTD Business Update Revenue Adj. EBITDA1 NT$17,453m +84% YoY R&D 505(b)(2) NDA Filing for Cabozantinib 1H26 1H26 NT$6,301m +50% YoY (LP757) was accepted with PDUFA date of 23 December 2026 2Q26 NT$8,809m +2% QoQ 2Q26 NT$3,338m +13% Q
Slide 6: YTD Pipeline Updates
6 YTD PIPELINE UPDATES Filing Approval Launch** 59 Submissions 49 Approvals 250 SKUs • 8 505(b)(2) • 1 505(b)(2) • 2 NCE • 10 NCE • 1 NCE • 16 505(b)(2) • 5 Biosimilar • 1 Biosimilar • 232 Complex Gx • 7 Brand • 46 Complex Gx • 29 Complex Gx Key Filings Key Approvals Key Launches LP757 (Cabozantinib
Slide 7: Lotus Active Pipeline Projects Overview
Lotus Active Pipeline Projects Overview 7 Active Specialty Products with 135 projects targeting US$125bn+ market Market Footprint 81% Strong Competitive Profile at Launch 46 Filed or Approved JP 4 MY 13 Expected Launch Timeline HK 13 SG 18 KR 19 PH 21 Near -term Mid -term Long -term TW 21 2026-2028
Slide 8: Selected High-Potential Pipeline Opportunities
Selected High-Potential Pipeline Opportunities 8 Project Therapeutic Regulatory Target Market Size* Launch Status Area Pathway Market (USD) Profile Project A Anti-Infective Generic (ANDA) US ~$3bn Limited Competition Filed Project B Respiratory Generic (ANDA) US < $0.5bn Limited Competition Filed Pr
Slide 9: Financial Information
02 FINANCIAL INFORMATION
Slide 10: 1H26 Financial Results
10 1H26 Financial Results (in NTD millions, except for EPS) 1H 26 Financial Highlights Key Financials • Consolidated revenue increased by 84% YoY, mainly driven 1H 26 1H 25 YoY by the acquisition of Alvogen and B2B sales Consolidated Revenue 17,453 9,477 +84.2% Cost of Goods (8,339) (3,768) 121.3% •
Slide 11: 1H26 Revenue +84% YoY
11 1H26 Revenue +84% YoY +84% YoY US NT$17,453mn 18,000 6,897 17,000 16,000 15,000 14,000 Asia +180% YoY 13,000 B2B z 12,000 11,000 +1% YoY 1,042 NT$9,475mn 10,000 78 21 +245% YoY -27 -35 9,000 z 8,000 1H25 KR TW SEA RoA B2B US 1H26
Slide 12: Diversification Across Therapies and Markets
12 Diversification Across Therapies and Markets Diversified Portfolio Revenue Breakdown YTD 1H26 Revenue Breakdown by TA Other 20% Therapeutic 33% Oncology & Areas 4% Immunology US 62% 17% B2B Brand RoA Endocrinology Biosimilar /Diabetes 2% SEA 3% TW 76% Cardiovascular 8% Generic 1% KR 30% Primary C
Slide 13: Healthy Operating Cash and Moderate Leverage
13 Healthy Operating Cash and Moderate Leverage Adj. EBITDA* (NT$mn) Adj. EBITDA* Margin(%) Pro-forma** NET DEBT/LTM Adj. EBITDA* (x) 44 2.97 36 6,301 4,202 0.86 1H 25 1H 26 1H 25 1H 26 Jun 25 Jun 26 *EBITDA =EBIT + Depreciation + Amortization + Impairment + Share-Based Payment + One-off Items ** Pr
Slide 14: Business Update
03 | nf : BUSINESS i UPDATE
Slide 15: Strong First-Half Foundation, Focused Execution Ahead
15 Strong First-Half Foundation, Focused Execution Ahead Strong First-Half Continued Execution 1 2 Execution Momentum Record revenue, strong operating Focused on launches and further R&D performance and strategic progress / BD milestones • Record 1H revenue, adj. EBITDA grew 50% YoY • Nintedanib and
Slide 16: Appendix
APPENDIX
Slide 17: 2026 YTD Pipeline Projects Highlights - R&D
2026 YTD Pipeline Projects Highlights - R&D 17 66 projects targeting US$58bn+ market R&D Projects by Launch Profile1 R&D Projects by Regulatory Pathway ` Exclusivity- Proof of Under Filed or Protected Concept Development Approved 56% Limited- Competition 6% Total 505(b)(2) 11 - 4 15 Total ANDA First
Slide 18: 2026 YTD Pipeline Projects Highlights - BD
2026 YTD Pipeline Projects Highlights - BD 18 69 projects targeting US$67bn+ market BD Projects by Regulatory Pathway Under Under Filed or BD Projects by Launch Profile1 Negotiation Development Approved Limited- Exclusivity- Total Competition Protected 13% 10 1 4 NDA 22% 15 Total Brand Acquisition 9
Slide 19: An international pharmaceutical company with global presence
An international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines https://www.lotuspharm.com.tw/ +886 2 2700 5908 info@lotuspharm.com in www.linkedin.com/company/lotus-pharmaceutica